Zhang Xinyu, Ji Hao, Huang Yeqing, Zhu Bingye, Xing Qianwei
Department of Urology, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, China.
Department of Urology, Tumor Hospital Affiliated to Nantong University, Nantong, 226001, Jiangsu Province, China.
Heliyon. 2023 Jan 24;9(2):e13201. doi: 10.1016/j.heliyon.2023.e13201. eCollection 2023 Feb.
PTTG1 has been reported to be linked with the prognosis and progression of various cancers, including kidney renal clear cell carcinoma (KIRC). In this article, we mainly investigated the associations between prognosis, immunity, and PTTG1 in KIRC patients.
We downloaded transcriptome data from the TCGA-KIRC database. PCR and immunohistochemistry were used, respectively, to validate the expression of PTTG1 in KIRC at the cell line and the protein levels. Survival analyses as well as univariate or multivariate Cox hazard regression analyses were used to prove whether PTTG1 alone could affect the prognosis of KIRC. The most important point was to study the relationship between PTTG1 and immunity.
The results of the paper revealed that the expression levels of PTTG1 were elevated in KIRC compared with para-cancerous normal tissues, validated by PCR and immunohistochemistry at the cell line and the protein levels (P < 0.05). High PTTG1 expression was related to shorter overall survival (OS) in patients with KIRC (P < 0.05). Through univariate or multivariate regression analysis, PTTG1 was confirmed to be an independent prognostic factor for OS of KIRC (P < 0.05), and its related seven pathways were obtained through gene set enrichment analysis (GSEA; P < 0.05). Moreover, tumor mutational burden (TMB) and immunity were found to be significantly connected with PTTG1 in KIRC (P < 0.05). Correlations between PTTG1 and immunotherapy responses implied that the low-PTTG1 group was more sensitive to immunotherapy (P < 0.05).
PTTG1 was closely associated with TMB or immunity, and it had a superior ability to forecast the prognosis of KIRC patients.
据报道，垂体瘤转化基因1（PTTG1）与包括肾透明细胞癌（KIRC）在内的多种癌症的预后和进展相关。在本文中，我们主要研究了KIRC患者的预后、免疫与PTTG1之间的关联。
我们从TCGA-KIRC数据库下载了转录组数据。分别采用聚合酶链反应（PCR）和免疫组织化学方法，在细胞系和蛋白质水平验证PTTG1在KIRC中的表达。采用生存分析以及单因素或多因素Cox风险回归分析，以证明PTTG1是否单独影响KIRC的预后。最重要的是研究PTTG1与免疫的关系。
本文结果显示，与癌旁正常组织相比，KIRC中PTTG1的表达水平升高，通过细胞系和蛋白质水平的PCR及免疫组织化学验证（P<0.05）。PTTG1高表达与KIRC患者较短的总生存期（OS）相关（P<0.05）。通过单因素或多因素回归分析，PTTG1被确认为KIRC患者OS的独立预后因素（P<0.05），并通过基因集富集分析（GSEA）获得了其相关的七条通路（P<0.05）。此外，发现肿瘤突变负荷（TMB）和免疫在KIRC中与PTTG1显著相关（P<0.05）。PTTG1与免疫治疗反应之间的相关性表明，低PTTG1组对免疫治疗更敏感（P<0.05）。
PTTG1与TMB或免疫密切相关，并且在预测KIRC患者的预后方面具有卓越能力。
